Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Neurogene Inc. (NASDAQ:NGNE) have been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $44.00.

Several equities analysts have recently commented on NGNE shares. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd. Lifesci Capital started coverage on Neurogene in a research report on Monday, January 26th. They issued an “outperform” rating and a $50.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of Neurogene in a research report on Tuesday, January 13th. Finally, Wall Street Zen cut Neurogene from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th.

Neurogene Trading Up 0.7%

Shares of NGNE opened at $17.00 on Friday. The company’s 50-day moving average price is $18.97 and its 200 day moving average price is $21.62. Neurogene has a 12-month low of $6.88 and a 12-month high of $37.27. The firm has a market cap of $263.33 million, a P/E ratio of -4.14 and a beta of 1.59.

Neurogene (NASDAQ:NGNE) last announced its earnings results on Thursday, November 13th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.27. Equities research analysts forecast that Neurogene will post -4.27 earnings per share for the current year.

Institutional Trading of Neurogene

Several hedge funds have recently made changes to their positions in NGNE. Balyasny Asset Management L.P. purchased a new position in shares of Neurogene in the third quarter valued at approximately $12,114,000. ArrowMark Colorado Holdings LLC lifted its holdings in Neurogene by 1.8% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 595,839 shares of the company’s stock worth $10,326,000 after buying an additional 10,442 shares in the last quarter. Jennison Associates LLC boosted its position in Neurogene by 35.3% in the 4th quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock valued at $10,982,000 after buying an additional 138,999 shares during the period. Geode Capital Management LLC boosted its position in Neurogene by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 249,695 shares of the company’s stock valued at $5,145,000 after buying an additional 3,262 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of Neurogene by 122.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 162,018 shares of the company’s stock worth $3,338,000 after acquiring an additional 89,216 shares in the last quarter. Institutional investors and hedge funds own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.